Presentaci

1
(No Transcript)
2
THE CURRENT APPROACH TO DES MARKET IS BASED ON
DRUG
DES arena
3
Active APPROACH IS LEVERAGED
4
Active APPROACH IS LEVERAGED
5
PLATFORM APOLO 3 STENT
STENT APOLO3

• Stainless Steel
• Open Cell Structure
• Diameters 3,00-4,50mm
• High Uniform Radial Force
• Superior Flexibility
• Low Recoil (1)
• Good trackability
• 5F Guiding Catheter

• Stainless Steel
• Open Cell Structure
• Diameters 2,00-2,75mm
• High Uniform Radial Force
• Superior Flexibility
• Low Recoil (1)
• Good trackability
• 5F Guiding Catheter

6
PLATFORM APOLO 3 STENT
STENT APOLO3 - WIDTH
0,0045
0,0041
0,0033
0,0033
0,0049
0,0045

• Superior Flexibility
• Entry Profile 0,017

7
PLATFORM APOLO 3 STENT
STENT APOLO3 STRUT THICKNESS
0,0045
0,0037

• Strut Thickness 0.0045
• Excellent Crossing Profile
• (0.038 - 0,041)

• Strut Thickness 0.0037
• Excellent Crossing Profile
• (0.034 - 0,038)

8
PLATFORM APOLO 3 STENT
STENT APOLO3 CROWNS AND CONNECTORS

• 6 Crowns
• 3 Connectors in spiral shape
• Superior flexibility
• High Uniform Radial Force
• Low Recoil (1)

9
PLATFORM APOLO 3 STENT
STENT APOLO3 CROWNS AND CONNECTORS

• 5 Crowns
• 2 Connectors in spiral shape
• Superior flexibility
• High Uniform Radial Force
• Low Recoil (1)

10
PLATFORM APOLO 3 STENT
PHYSICO-MECHANICAL PROPERTIES (COATING)
SMOOTHNESS
No turbulence
No roughness
No friction
Pre-crimping
Post-crimping
The Polymer is fixed to the stent thanks to a
unique and proprietary Iberhospitex-Cordynamic
process
11
PLATFORM APOLO 3 STENT
PHYSICO-MECHANICAL PROPERTIES (COATING)
NO CRACK-BRIDGING
A
B

• No modification of mechanical integrity
• Surface protection
• Non crackable

12
PLATFORM APOLO 3 STENT
PHYSICO-MECHANICAL PROPERTIES (COATING)
NO STICKY
B

• Easy balloon withdrawal
• Non fragment detachment
• Drug release homogeneity

13
IRIST APPROACH IS LEVERAGED
14
POLYMER P-5
Copolymer of methacrylic monomer containing
Triflusal butyl acrylate

• High molecular weight
• High hydrolytic stability
• Good drug loading
• High biocompatibility
• Biostable
• Antiplatelet
• Anti-inflammatory

The Polymer is patented and developed for DES
applications by a co-development between
Laboratorios Uriach and Iberhospitex-Cordynamic
15
POLYMER P-5
BIOSTABLE
Triflusal Release
HTB Released
Days
16
POLYMER P-5
GOOD DRUG SUPPORT
Compatibility of P-5 Polymer with different drugs
Drug Polymer
17
POLYMER P-5
BIOLOGICAL PROPERTIES OF TRIFLUSAL
NON PLATELET ADHESION
Control Pre-incubation with Platelet-rich plasma
Control Post-incubation with Platelet-rich plasma
Control Post-incubation with Platelet-rich plasma
Polymer P-5 Pre-incubation With platelet-rich
plasma
Polymer P-5 Pre-incubation With platelet-rich
plasma
Polymer P-5 Post-incubation With platelet-rich
plasma
Polymer P-5 Post-incubation With platelet-rich
plasma
18
POLYMER P-5
BIOLOGICAL PROPERTIES OF TRIFLUSAL
BIOCOMPATIBLE OSTEOBLASTS AND FIBROBLASTS
Polymer P-5
Control

• Normal cell adhesion
• Standard cell growing
• Normal morphology

19
POLYMER P-5
BIOLOGICAL PROPERTIES OF TRIFLUSAL
BIOCOMPATIBLE EX-VIVO PLATELET DEPOSITION
(Badimons Camera)

• Non thrombogenic

Source Catalan Institute of Cardiovascular
Sciences (Barcelona)
20
POLYMER P-5
BIOLOGICAL PROPERTIES OF TRIFLUSAL
BIOCOMPATIBLE IN-VITRO PLATELET ADHESION (Static
Conditions)

• Non thrombogenic

Source Catalan Institute of Cardiovascular
Sciences (Barcelona)
21
ACTIVE APPROACH IS LEVERAGED
22
DRUG PACLITAXEL

• Paclitaxel - Effective anti-proliferative drug
• Numerous studies demonstrated the positive
  effects of Paclitaxel on inhibiting Smooth Muscle
  Cell (SMC) proliferation and migration.
• Paclitaxel supports an uniform drug distribution
  and suppresses the formation of neointimal
  hyperplasia due to its lipophilic property.

23
DRUG PACLITAXEL